- Olmo's Barcelona registration battle puts Laporta under pressure
- Taste of 2034 World Cup as Saudi Asian Cup stadiums named
- Eurozone inflation picks up in December
- France flanker Ollivon out for season, to miss Six Nations
- S. Korea investigators get new warrant to arrest President Yoon
- Tottenham trigger Son contract extension
- China's most successful team kicked out of professional football
- Eyeing green legacy, Biden declares new national monuments
- South Korea rival parties form plane crash task force
- Georgians hold anti-government protest on Orthodox Christmas
- Japan actor fired from beer ad after drunken escapade
- Nvidia ramps up AI tech for games, robots and autos
- Blinken says US-Japan ties solid despite rift over steel deal
- Quake in China's Tibet kills 95 with tremors felt in Nepal, India
- Taiwan says Chinese-owned ship suspected of damaging sea cable goes dark
- North Korea's Kim says new hypersonic missile will deter 'rivals'
- Sinner turns focus to Australian Open defence after 'amazing' year
- Ostapenko begins Adelaide title defence with comeback win
- Asian markets mostly up after tech-fuelled Wall St rally
- Pace of German emissions cuts slows in 2024: study
- McDonald's rolls back some of its diversity practices
- Giannis triple-double propels Bucks over Raptors
- S. Korea rival parties form plane crash task force despite political turmoil
- Quake in China's Tibet kills 53 with tremors felt in Nepal, India
- Olmo situation overshadowing Barca bid for Spanish Super Cup
- Winter storm leaves large US region blanketed in snow, ice
- Hewitt's son Cruz out of Australian Open qualifying at first hurdle
- Quake in China's Tibet kills 32 with tremors felt in Nepal, India
- Blinken says US-Japan ties rock solid despite rift over steel deal
- Osaka splits with rapper Cordae ahead of Australian Open
- Sabalenka to Andreeva: Five women to watch at the Australian Open
- Sabalenka eyes Australian Open hat-trick but Swiatek, Gauff lurk
- Asian markets mostly rise after tech-fuelled Wall St rally
- Blinken in Japan after rift on steel deal
- Ex-England skipper Vaughan backs shake-up 'to keep Test cricket relevant'
- S. Korea investigators seek new warrant to arrest President Yoon
- North Korea's Kim says new missile will deter 'rivals'
- France to remember Charlie Hebdo attacks 10 years on
- 'Comeback' queen Demi Moore 'has always been here,' says director
- Homes talk and tables walk at AI dominated CES
- Kyrgios set for Davis Cup return after five years
- Golden Globes ratings edge up past 10 million
- USA striker Vazquez joins Austin in club record deal
- MainStreetChamber Holdings, Inc. Appoints Anthony (Tony) Anish as Chief Financial Officer and Announces Key Leadership Transitions
- Wing Luke Museum Celebrates the 100th Birthday of Civil Rights Icon, Wing Luke
- Argo Blockchain PLC Announces December Operational Update
- Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement with the Medtronic Spinal Division
- Meta Names UFC boss Dana White, a Trump ally, to board
- Tensions mount in Venezuela ahead of Maduro swearing-in
- Judge rejects Trump request to delay hush money sentencing
France to 're-shore' production of 50 key medicines: Macron
France will bring home production of around 50 crucial medications for which it currently depends on imports, President Emmanuel Macron said Tuesday, hoping to battle shortages of items like antibiotics and paracetamol.
Of the initial slate of drugs with a "clear dependence on imports from outside the EU", 25 "will have their production re-shored or significantly increased... in the coming weeks," Macron said during a visit to a pharmaceuticals factory in southern France.
The announcement comes after a March survey by pollsters BVA found 37 percent of people had already run into shortages at the pharmacy.
Up to 80 percent of familiar medications like antibiotics and painkillers used in France are produced abroad, especially in China.
Some of the drugs are still made in France, but at volumes that fail to match demand.
Over the winter, Europe faced shortages of key antibiotic amoxicillin and other medications as surging illnesses particularly among children have increased demand for the drugs.
Under Macron's plan, public money to the tune of 160 million euros ($173 million) will go to support eight of the new projects, including for amoxycillin -- produced by British pharma giant GSK in northwestern France -- as well as anaesthetics, painkillers and cancer drugs.
Companies would be able to apply for a share of a further 50 million euros in funding, Macron said.
The 50 drugs flagged by Macron are among a list of 450 drawn up by the health ministry for which "we must absolutely secure our supply chains, either by completely re-shoring or diversifying (supply) and continuing to innovate," the president said.
Tuesday's pharma announcements mark the first step in a week dedicated to industrial projects, which Macron hopes will move public attention on from the battles over his widely-disliked pension reform.
B.Finley--AMWN